

Published on *BupPractice* (<http://local.buppractice.com>)

[Home](#) > Buprenorphine Product Formulations Comparison

Buprenorphine Product Formulations Comparison ^[1]

Description:

Compares the different formulations of buprenorphine products made by different drug companies.

Product	How Supplied (Buprenorphine / Naloxone mg)	Induction Dosage Increments (until opioid withdrawal signs and symptoms are suppressed)	Recommended Target Dose for Maintenance	Instructions for Use
Suboxone® Sublingual Film Reckitt Benckiser	2 mg bup./0.5 mg nal. 4 mg bup./1 mg nal. 8 mg bup./2 mg nal. 12 mg bup./3 mg nal.	Increments/decrements of 2 mg bup./0.5 mg nal. or 4 mg bup./1 mg nal. up to 8 mg bup./ 2 mg nal. day 1 (in divided doses at around 2 hour intervals) Day 2, administer up to 16 mg bup./4 mg nal. of sublingual film single daily dose.	Target Dose: 16 mg bup./4 mg nal. single daily dose (Range: 4 mg bup./1 mg nal. to 24 mg bup./6 mg nal. per day)	Place film under the tongue, close to the base on the left or right side. Must be kept under tongue until completely dissolved.

Product	How Supplied (Buprenorphine / Naloxone mg)	Induction Dosage Increments (until opioid withdrawal signs and symptoms are suppressed)	Recommended Target Dose for Maintenance	Instructions for Use
Zubsolv® Sublingual Tablet Orexo	1.4 mg bup./0.36 mg nal. 5.7 mg bup./1.4 mg nal. Dissolves more rapidly, menthol flavor, and smaller tablet.	Increments/decrements of 1.4 mg bup./0.36 mg nal. or 2.8 mg bup./0.72 mg nal.	Target Dose: 11.4 mg bup./2.8 mg nal. single daily dose (Range: 2.8 mg bup./0.72 mg nal. to 17.1 mg bup./4.2 mg nal. per day) Conversion Information: One ZUBSOLV 5.7 mg bup./1.4 mg nal. sublingual tablet equivalent to one SUBOXONE 8 mg bup./2 mg nal. sublingual tablet	Tablet should be placed under the tongue until dissolved. Do not cut, chew, or swallow tablets.
Bunavail™ Buccal Film BioDelivery Sciences International	2.1 mg bup./ 0.3 mg nal. 4.2 mg bup./ 0.7 mg nal. 6.3 mg bup./ 1 mg nal. Half a normal dose can achieve same result as other products, due to twice the bioavailability.	Increments/decrements of 2.1 mg bup./0.3 mg nal.	Target Dose: 8.4 mg bup./1.4 mg nal. per day single daily dose (Range: 2.1 mg bup./0.3 mg nal. to 12.6 mg bup./2.1 mg nal. per day). Conversion information: BUNAVAIL 4.2 mg bup./0.7 mg nal. buccal film equivalent to a SUBOXONE 8 mg bup./2 mg nal. sublingual tablet	Wet the inside of the cheek. Hold the film with the text (BN2, BN4, or BN6) facing up and place that side with the text against the inside of the cheek. Press and hold the film in place for 5 seconds.

Product	How Supplied (Buprenorphine / Naloxone mg)	Induction Dosage Increments (until opioid withdrawal signs and symptoms are suppressed)	Recommended Target Dose for Maintenance	Instructions for Use
Generic Buprenorphine HCl & Naloxone HCl Dihydrate Sublingual Tablets Actavis Elizabeth LLC	2 mg bup./0.5 mg nal. 8 mg bup./2 mg nal.	Increments/decrements of 2 mg bup./0.5 mg nal. or 4 mg bup./1 mg nal.	Target Dose: 16 mg bup/4 mg nal. single daily dose (Range: 4 mg bup./1 mg nal. to 24 mg bup./6 mg nal. per day).	Tablet should be placed under the tongue until it is dissolved.
Buprenorphine (Without Naloxone) HCl Sublingual Tablet Roxane Laboratories, Inc	2 mg bup. 8 mg bup.	Increment/decrements of 2 mg or 4 mg bup Up to 8 mg bup on Day 1 and 16 mg bup on Day 2.	Target Dose: 16 mg bup single daily dose (Range: 4 mg bup. to 24 mg bup. per day).	Put the tablet(s) under your tongue. Let them dissolve completely. While the tablets are dissolving, do not chew or swallow the tablet. Talking while the tablet is dissolving can also affect absorption.
Probuphine® Subdermal Implant Titan Pharmaceuticals, Braeburn Pharmaceuticals	One inch long rods containing buprenorphine	For use in patients already stable on a low to moderate dose of 8 mg buprenorphine or less per day. Placed surgically. Replaced at 6 months.	Target dose is 8 mg or less per day	Implant is typically placed inside the upper arm, under the skin, for 6 months. Requires specific REMS training and certification for the physician to insert and remove.

Product	How Supplied (Buprenorphine / Naloxone mg)	Induction Dosage Increments (until opioid withdrawal signs and symptoms are suppressed)	Recommended Target Dose for Maintenance	Instructions for Use
Sublocade™ Injectable Invidior	Comes pre-filled syringes with a 19 gauge 5/8-inch needle. In 100mg and 300 mg doses. Prescribe for individual patient and have it sent from a certified pharmacy or become a REMS-certified clinic. Not dispensed to the patient.	Not used for induction. For use after patient is stabilized for at least one week on transmucosal buprenorphine.	Target Dose: 300 mg monthly for two months, then 100 mg monthly but may be increased up to 300 mg if needed. See product information for details.	Once monthly subcutaneous injection by a qualified health care provider after dose stabilized at least one week on submucosal buprenorphine. Forms visible depot under the skin from which medication is slowly released over time.

Links:

[1] <http://local.buppractice.com/node/5863>